One-year results of the intravitreal administration of faricimab in patients with naïve type 3 macular neovascularization. [PDF]
Int J Retina VitreousSaito M, Imaizumi K.
europepmc +1 more source
Bilateral Eales' Disease Managed With Vitrectomy and Anti-VEGF Therapy: A Case Report. [PDF]
Am J Case RepLelek Z +7 more
europepmc +1 more source
Comparison of Short-term Outcomes Between Faricimab and High-Dose Aflibercept in Patients With Neovascular Age-related Macular Degeneration. [PDF]
J Vitreoretin DisShiratori M +4 more
europepmc +1 more source
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series [PDF]
Eandi, Chiara
core +1 more source
Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration. [PDF]
J Vitreoretin DisKlufas MA +3 more
europepmc +1 more source
Management of diabetic macular edema: from anti-VEGF to emerging therapies. [PDF]
Front Med (Lausanne)Ji M, Wei W, Gong H, Zhang G.
europepmc +1 more source
Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration. [PDF]
CureusKaganovski A, Rostomian N, Shrier E.
europepmc +1 more source
U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]
PLoS OneMalhotra K +4 more
europepmc +1 more source
Early anatomical outcomes of faricimab vs aflibercept 2 mg in treatment-naïve neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: A head-to-head comparative study in Taiwan. [PDF]
J Chin Med AssocYang CC +6 more
europepmc +1 more source